ANAB logo

ANAB
AnaptysBio Inc

2,056
Mkt Cap
$1.75B
Volume
396,310.00
52W High
$72.36
52W Low
$11.40
PE Ratio
-55.92
ANAB Fundamentals
Price
$60.41
Prev Close
$60.08
Open
$59.93
50D MA
$52.09
Beta
0.82
Avg. Volume
684,791.70
EPS (Annual)
-$0.4601
P/B
137.58
Rev/Employee
$2.26M
$1,373.19
Loading...
Loading...
News
all
press releases
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
News Placeholder
More News
News Placeholder
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
News Placeholder
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
News Placeholder
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
News Placeholder
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026...
News Placeholder
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
News Placeholder
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
News Placeholder
Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down
ZTS misses on Q1 earnings and cuts its 2026 revenue outlook as weaker U.S. companion animal sales pressured results, sending shares down in pre-market trading.
News Placeholder
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
News Placeholder
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available